Published in J Virol on March 01, 2000
Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis (2000) 2.69
Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol (2009) 1.45
A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol (2005) 1.42
Pathogenesis of Lassa fever. Viruses (2012) 1.23
A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine (2007) 1.13
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol (2006) 1.07
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology (2006) 1.06
Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol (2011) 1.02
A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog (2009) 0.97
Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles. J Virol (2009) 0.97
Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog (2015) 0.96
Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J Hum Virol (2001) 0.91
Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice. Clin Diagn Lab Immunol (2005) 0.91
Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog (2006) 0.91
Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90
Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J Med Virol (2004) 0.88
Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. PLoS Pathog (2013) 0.87
Immune responses and Lassa virus infection. Viruses (2012) 0.86
The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines (2013) 0.84
Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. Immunome Res (2010) 0.83
Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system. Microbiol Mol Biol Rev (2010) 0.83
Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. PLoS Negl Trop Dis (2014) 0.81
Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. J Vaccines Vaccin (2012) 0.79
Arenavirus evasion of host anti-viral responses. Viruses (2012) 0.79
Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathog (2016) 0.77
Immunobiology of Ebola and Lassa virus infections. Nat Rev Immunol (2017) 0.77
Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization. J Virol (2002) 0.76
Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man. Future Virol (2015) 0.75
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity (1998) 17.27
Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 10.03
Two populations of Ia-like molecules on a human B cell line. J Immunol (1980) 7.68
Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity (1998) 6.29
A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis (1987) 5.27
A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis (1987) 3.51
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Clinical virology of Lassa fever in hospitalized patients. J Infect Dis (1987) 2.94
Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected]. Nature (1996) 2.25
Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg (1996) 1.70
CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med (1996) 1.62
HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. Eur J Immunogenet (1991) 1.50
Long-term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection. J Virol (1998) 1.33
Stability of virus-specific CD4+ T cell frequencies from acute infection into long term memory. J Immunol (1998) 1.29
Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet (1987) 1.28
Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology (1989) 1.25
Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A (1989) 1.25
Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. J Clin Microbiol (1998) 1.24
Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg (1985) 1.23
Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet (1979) 1.14
Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies. Arch Virol (1989) 1.12
Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res (1988) 1.11
Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4. Virology (1998) 1.08
Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J Virol (1993) 1.06
Quantification of epitope-specific MHC class-II-restricted T cells following lymphocytic choriomeningitis virus infection. Cell Immunol (1999) 0.95
Host-parasite interaction in human onchocerciasis: identification and sequence analysis of a novel human calgranulin. Biochem Biophys Res Commun (1996) 0.94
Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development. Med Microbiol Immunol (1986) 0.88
Dissection of human allostimulatory determinants with cloned T cells: stimulation inhibition by monoclonal antibodies TU22, 34, 35, 36, 37, 39, 43, and 58 against distinct human MHC class II molecules. Hum Immunol (1985) 0.86
Current progress towards vaccines for arenavirus-caused diseases. Vaccine (1992) 0.84
Production of both IFN-gamma and IL-5 by Onchocerca volvulus S1 antigen-specific CD4+ T cells from putatively immune individuals. Int Immunol (1997) 0.84
Standardization of a plaque assay for Lassa virus. J Med Virol (1987) 0.84
Vibrational spectroscopy of bacteriorhodopsin mutants: light-driven proton transport involves protonation changes of aspartic acid residues 85, 96, and 212. Biochemistry (1988) 4.93
Transmembrane protein structure: spin labeling of bacteriorhodopsin mutants. Science (1990) 4.07
Fine structure of lipid-depleted mitochondria. J Cell Biol (1967) 3.48
Worldwide epidemiology of human adenovirus infections. Am J Epidemiol (1983) 3.45
Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol (2009) 3.45
HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet (1993) 3.39
Aspartic acid substitutions affect proton translocation by bacteriorhodopsin. Proc Natl Acad Sci U S A (1988) 3.13
Aspartic acid-96 is the internal proton donor in the reprotonation of the Schiff base of bacteriorhodopsin. Proc Natl Acad Sci U S A (1989) 3.06
Detection of dengue virus RNA in patients after primary or secondary dengue infection by using the TaqMan automated amplification system. J Clin Microbiol (1999) 2.96
Isolation and characterization of Golgi membranes from bovine liver. J Cell Biol (1969) 2.92
Substitution of amino acids Asp-85, Asp-212, and Arg-82 in bacteriorhodopsin affects the proton release phase of the pump and the pK of the Schiff base. Proc Natl Acad Sci U S A (1990) 2.80
Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and results in filarial infertility. J Clin Invest (1999) 2.78
Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis (2000) 2.69
Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science (1985) 2.57
IgM antibodies to Epstein-Barr virus in infectious mononucleosis. Arch Gesamte Virusforsch (1972) 2.47
Detection of IgM antibodies to cytomegalovirus (CMV) using an enzyme-labelled antigen (ELA). J Gen Virol (1980) 2.13
Preparation and characterization of golgi membranes from rat liver. Biochim Biophys Acta (1970) 2.11
Determination of different cytomegalovirus immunoglobulins (IgG, IgA, IgM) by immunofluorescence. Arch Gesamte Virusforsch (1972) 2.04
Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet (2000) 2.04
Replacement of aspartic residues 85, 96, 115, or 212 affects the quantum yield and kinetics of proton release and uptake by bacteriorhodopsin. Proc Natl Acad Sci U S A (1989) 2.04
Wolbachia bacteria of filarial nematodes. Parasitol Today (1999) 1.95
Protonation state of Asp (Glu)-85 regulates the purple-to-blue transition in bacteriorhodopsin mutants Arg-82----Ala and Asp-85----Glu: the blue form is inactive in proton translocation. Proc Natl Acad Sci U S A (1990) 1.94
Tomographic 3D reconstruction of quick-frozen, Ca2+-activated contracting insect flight muscle. Cell (1999) 1.85
Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. Int Immunol (2000) 1.84
Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet (2001) 1.82
The biosynthesis of rat serum albumin. IV. Apparent passage of albumin through the Golgi apparatus during secretion. J Biol Chem (1971) 1.77
Solid-phase enzyme immunoassay for immunoglobulin M antibodies to cytomegalovirus. J Clin Microbiol (1977) 1.75
Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg (1996) 1.70
Site-directed isotope labelling and FTIR spectroscopy of bacteriorhodopsin. Nat Struct Biol (1994) 1.67
Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol (1994) 1.64
MG-160. A novel sialoglycoprotein of the medial cisternae of the Golgi apparatus [published eeratum appears in J Biol Chem 1989 Mar 5;264(7):4264]. J Biol Chem (1989) 1.62
T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol (1994) 1.62
Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol (1996) 1.61
Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction. J Clin Microbiol (1990) 1.61
Isolation and characterization of Golgi apparatus and membranes from rat liver. Methods Enzymol (1974) 1.61
Expression from the human occludin promoter is affected by tumor necrosis factor alpha and interferon gamma. J Cell Sci (2000) 1.60
Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet (1991) 1.56
Neutrophil accumulation around Onchocerca worms and chemotaxis of neutrophils are dependent on Wolbachia endobacteria. Microbes Infect (2001) 1.55
Lipid composition of mitochondria from bovine heart, liver, and kidney. J Lipid Res (1967) 1.50
A new approach to the treatment of filariasis. Curr Opin Infect Dis (2001) 1.48
Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature (1984) 1.48
Elephantiasis of non-filarial origin (podoconiosis) in the highlands of north-western Cameroon. Ann Trop Med Parasitol (2008) 1.44
The prevalence of antibodies to HIV-1 and HIV-2 in onchocerciasis-endemic rural areas in southern Benin. AIDS (1993) 1.44
The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol (1990) 1.44
Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J Infect Dis (2001) 1.40
Lipid composition of the Golgi apparatus of rat kidney and liver in comparison with other subcellular organelles. Biochim Biophys Acta (1975) 1.40
Structure-function studies on bacteriorhodopsin. IX. Substitutions of tryptophan residues affect protein-retinal interactions in bacteriorhodopsin. J Biol Chem (1989) 1.40
Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. J Immunol (1985) 1.40
A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem (1987) 1.39
Solubilization and properties of galactosyltransferase and sulfotransferase activities of Golgi membranes in Triton X-100. J Biol Chem (1978) 1.39
Immunomodulation by filarial nematodes. Parasite Immunol (2005) 1.38
IgM antibodies to cytomegalovirus during pregnancy. Arch Virol (1977) 1.38
Pig heart calpastatin: identification of repetitive domain structures and anomalous behavior in polyacrylamide gel electrophoresis. Biochemistry (1988) 1.38
X-ray diffraction indicates that active cross-bridges bind to actin target zones in insect flight muscle. Biophys J (1998) 1.38
Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur J Immunol (1992) 1.36
A novel pathway of human T cell activation via a 103 kD T cell activation antigen. J Immunol (1987) 1.34
Microbial and chemical transformations of some 12,13-epoxytrichothec-9,10-enes. Appl Environ Microbiol (1978) 1.32
Arthroscopic treatment of septic joints: prognostic factors. Arch Orthop Trauma Surg (2002) 1.32
Cimetidine for anastomotic ulcers after partial gastrectomy. A randomized controlled trial. N Engl J Med (1979) 1.32
Improved detection of virus-specific IgM antibodies. Elimination of non-specific IgM binding. J Gen Virol (1978) 1.31
Bilateral thoracic extraadrenal myelolipoma. Eur J Cardiothorac Surg (2004) 1.31
Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. Am J Med (1975) 1.30
Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis (1989) 1.29
Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering. J Immunol (1986) 1.27
Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation (1982) 1.27
Short communication: Lassa fever in Sierra Leone: UN peacekeepers are at risk. Trop Med Int Health (2001) 1.26
Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme. J Virol (2001) 1.25
Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. J Clin Microbiol (1998) 1.24
Biosynthesis of lipids in Golgi complex and other subcellular fractions from rat liver. Biochim Biophys Acta (1974) 1.23
Orientation of glycoprotein galactosyltransferase and sialyltransferase enzymes in vesicles derived from rat liver Golgi apparatus. J Cell Biol (1981) 1.23
Antibodies to human cytomegalovirus structural polypeptides during primary infection. J Virol Methods (1988) 1.23
Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine. Gut (1982) 1.22
Cross-reactivity in flavivirus serology: new implications of an old finding? Med Microbiol Immunol (2002) 1.21
Infection of BALB/c mice with the filarial nematode Litomosoides sigmodontis: role of CD4+ T cells in controlling larval development. Infect Immun (1997) 1.20
Seroepidemiology of human immunodeficiency virus in Africa. Br Med J (Clin Res Ed) (1986) 1.20
Relationship between enterotoxic- and T lymphocyte-stimulating activity of staphylococcal enterotoxin B. J Immunol (1990) 1.20
Filariasis and lymphoedema. Parasite Immunol (2009) 1.20
Surface charge of bacteriorhodopsin detected with covalently bound pH indicators at selected extracellular and cytoplasmic sites. Biochemistry (1994) 1.18
In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J Immunol (1999) 1.17
The reaction of hydroxylamine with bacteriorhodopsin studied with mutants that have altered photocycles: selective reactivity of different photointermediates. Proc Natl Acad Sci U S A (1991) 1.17
A haemorrhagic fever from the Côte d'Ivoire. Lancet (1999) 1.17
Synovial fluid-derived Yersinia-reactive T cells responding to human 65-kDa heat-shock protein and heat-stressed antigen-presenting cells. Eur J Immunol (1991) 1.17
Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells. J Immunol (1990) 1.17
Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis. J Physiol (2001) 1.17
Diagnosis of human cytomegalovirus-induced retinitis in human immunodeficiency virus type 1-infected subjects by using the polymerase chain reaction. J Clin Microbiol (1991) 1.16
Orientation and role of nucleosidediphosphatase and 5'-nucleotidase in Golgi vesicles from rat liver. Biochemistry (1982) 1.16
Selective activation of T cell kinase p56lck by Herpesvirus saimiri protein tip. J Biol Chem (1996) 1.15
Vibrational spectroscopy of bacteriorhodopsin mutants. Evidence that ASP-96 deprotonates during the M----N transition. J Biol Chem (1991) 1.15
CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood (1990) 1.15
Some studies on the metabolism of phospholipids in Golgi complex from bovine and rat liver in comparison to other subcellular fractions. Biochim Biophys Acta (1971) 1.15
Duodenal biopsies of HIV-infected patients with diarrhoea exhibit epithelial barrier defects but no active secretion. AIDS (1998) 1.14
Detection of immunoglobulin M antibody to Epstein-Barr virus by use of an enzyme-labeled antigen. J Clin Microbiol (1982) 1.13
Response of synovial fluid T cell clones to Yersinia enterocolitica antigens in patients with reactive Yersinia arthritis. Clin Exp Immunol (1989) 1.13
Stimulation of human T cells by streptococcal "superantigen" erythrogenic toxins (scarlet fever toxins). J Immunol (1993) 1.13